Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up
Open Access
- 20 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5362-5366
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapyNature Medicine, 2024
- Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE studyBritish Journal of Haematology, 2024
- Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell TherapyJAMA Oncology, 2024
- T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyNature Medicine, 2024
- Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experienceBone Marrow Transplantation, 2022
- Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patientsBritish Journal of Haematology, 2022
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphomaCancer, 2006
- Second Cancers Among Long-term Survivors of Non-Hodgkin's LymphomaJNCI: Journal of the National Cancer Institute, 1993